Does beta-blocker therapy reduce all-cause mortality in patients with HFpEF?
Beta-blocker therapy may reduce all-cause mortality in HFpEF based on observational data, but does not appear to reduce heart failure rehospitalizations, highlighting the need for large-scale RCTs.
This meta-analysis showed that beta-blocker therapy has the potential to reduce all-cause mortality in patients with HFpEF based on observational studies. Nevertheless, it did not affect rehospitalization for heart failure or its composite with all-cause mortality. Large scale randomized trials are needed to clarify this uncertainty.
Kaddoura et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: